摘要
目的观察奥氮平联合5-HT3受体拮抗剂及地塞米松防治化疗相关性呕吐的疗效和不良反应。方法将60例化疗患者随机分为研究组(30例)及对照组(30例)。两组均在化疗前,常规应用5-HT3受体拮抗剂及地塞米松止吐,研究组在常规止吐的基础上,加用奥氮平。化疗结束后,比较两组控制急性和延迟性CINV的疗效差别及不良反应。结果研究组和对照组急性CINV的发生率6.67%(2/30)和16.67%(5/30),组间数据比较,差异不具有统计学意义(P>0.05);延迟性CINV的发生率分别为3.33%(1/30)和26.7%(8/30),组间数据比较,差异不具有统计学意义(P>0.05)。治疗期间,研究组中,70.00%(21例)患者在服用奥氮平期间出现了嗜睡;对照组中,66.67%(20例)患者出现了睡眠障碍。结论奥氮平联合5-HT3受体拮抗剂及地塞米松防治化疗相关性CINV具有较好的临床效果,同时能够提高肿瘤患者在化疗期间的生活质量。
Objective To observe the effcacy and side effects of olanzapine combined with 5-HT3 receptor antagonist and dexamethasone in the treatment of chemotherapy-associated vomiting. Methods 60 patients were randomly divided into study group （30 cases） and control group （30 cases）. Both groups were treated with 5-HT3 receptor antagonist and dexamethasone antiemetic before chemotherapy. The study group added olanzapine on the basis of routine antiemetic. After treatment, the difference between the two groups in controlling the acute and delayed CINV was compared. Results The incidence of acute CINV in the study group and the control group was 6.67% （2/30） and 16.67% （5/30）, and the difference between the groups was not statistically significant （P 〉 0.05）. The incidence of delayed CINV was 3.33% （1/30） and 26.67% （8/30） respectively, and the difference between groups was not statistically significant （P 〉 0.05）. During the treatment period, 70.00% （21 cases） of patients in the study group experienced somnolence during taking olanzapine. In the control group, 66.67% （20 cases） of patients had sleep disorders. Conclusion Ozapine combined with 5-HT3 receptor antagonist and dexamethasone have good effect on CINV and can improve the quality of life of tumor patients during chemotherapy.
作者
郭秀梅
林雪
GUO Xiumei;LIN Xue(Department of Oncology,Jilin People＇s Hospital,Jilin Jilin 132001,China)
出处
《中国继续医学教育》
2018年第22期124-126,共3页
China Continuing Medical Education
